They found TLR2 expression was elevated in wounded tumor cells, and by creating an in vitro assay of wound healing, peptidoglycan (PGN), a TLR2 agonist, was revealed to accelerate the wound repair, while the dominant negative forms of TLR2 or MyD88 could significantly inhibit the process. The gene discussed is TLR2; the disease is neoplasm.